ABCB1 and early-onset autosomal dominant Alzheimer disease: The comprehensive assessment integrated machine learning BBB predictions, P-glycoprotein efflux liability evaluation, and Alzheimer’s-disease-specific evidence classification to generate rankings that balance computational predictions with realistic pharmaceutical development requirements and translational feasibility considerations.